Exploration of potential active ingredients and mechanism of action of Xihuang pill-medicated serum against glioma based on HPLC-Q-TOF-MS/MS, network pharmacology and experimental verification
10.16438/j.0513-4870.2023-0750
- VernacularTitle:基于HPLC-Q-TOF-MS/MS、网络药理学及实验验证探讨西黄丸含药血清抗脑胶质瘤的潜在活性成分及作用机制
- Author:
Jing PAN
1
;
Qi-hai ZHANG
2
;
Hao-wen FAN
1
;
Xia WANG
3
;
Wei-feng YAO
4
;
Hong-bin XU
5
Author Information
1. The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210017, China
2. The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210017, China; Northern Jiangsu People's Hospital, Yangzhou 225001, China
3. The Second Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Second Chinese Medicine Hospital), Nanjing 210017, China
4. School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China
5. The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210017, China; Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo 315010, China
- Publication Type:Research Article
- Keywords:
Xihuang pill;
medicated serum;
HPLC-Q-TOF-MS/MS;
ingredient absorbed into blood;
glioma
- From:
Acta Pharmaceutica Sinica
2024;59(3):693-703
- CountryChina
- Language:Chinese
-
Abstract:
Qualitative analysis of the ingredients absorbed into blood and their metabolites of Xihuang pill (XHP) were conducted using high-performance liquid chromatography quadrupole time-of-flight mass spectrometry (HPLC-Q-TOF-MS/MS) technology. Network pharmacology was used to explore the potential anticancer mechanisms of the ingredients against glioma, and their specific mechanisms were validated through molecular docking and experimental verification. SD rats were intragastrically administered with XHP, and rat serum samples were collected. Ingredients absorbed into blood and their metabolites were identified based on the retention time of chromatographic peaks, accurate molecular mass, characteristic fragment ions, and comparisons with reference substances and literature data. PharmMapper and SwissTarget Prediction databases were used to obtain the targets of the XHP-medicated serum, while GeneCards, OMIM, PharmGKB, TTD, and DrugBank databases were used to obtain glioma disease targets. The "component-target" network relationship diagram was constructed using Cytoscape 3.9.1 software. The protein-protein interaction (PPI) network diagram was constructed using the STRING database, and the targets were analyzed using GO and KEGG analyses. Molecular docking was used to verify the binding ability of core targets with their corresponding compounds in XHP-medicated serum. The potential mechanism of the anti-glioma effect of 11-keto-β-boswellic acid (KBA), a representative component of XHP-medicated serum, was verified using CCK-8 and Western blot assays. A total of 40 compounds were identified in the XHP-medicated serum, including 28 prototype components and 12 metabolites. The network pharmacology results showed that elemonic acid, 3-acetyl-β-boswellic acid, KBA, α-boswellic acid, and other 5 compounds might be the active ingredients of XHP-medicated serum in the treatment of glioma. Glutathione reductase (GSR), glucose-6-phosphate dehydrogenase (G6PD), ATP-citrate lyase (ACLY), aldo-keto reductase family 1 member B1 (AKR1B1) and glutaredoxin (GLRX) were identified as key targets, involving pathways such as glutathione metabolism and the pentose phosphate pathway. Further cell experiments showed that KBA significantly inhibited the proliferation of T98G cells with an IC50 of 30.96 μmol·L-1, and KBA (30 μmol·L-1) significantly downregulated the protein expression levels of GSR in T98G cells. In summary, XHP-medicated serum may exert its anti-glioma effect by regulating GSR and G6PD-targeted pathways involved in glutathione metabolism. These results provide valuable evidence for further investigating the mechanism of XHP in treating glioma. The animal welfare and experimental procedures were approved by the Ethical Committee of Laboratory Animals at Nanjing University of Chinese Medicine (approval No. ACU221001).
